BJC Reports (Jul 2024)

Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia

  • Keita Kirito,
  • Albert Qin,
  • Shanshan Suo,
  • Rongfeng Fu,
  • Daoxiang Wu,
  • Toshiaki Sato,
  • Oleh Zagrijtschuk,
  • Kazuya Shimoda,
  • Norio Komatsu,
  • Jie Jin

DOI
https://doi.org/10.1038/s44276-024-00076-4
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 3

Abstract

Read online

Anaemia could develop in polycythemia vera (PV) due to phlebotomy-caused iron-deficiency and cytotoxic effect of cytoreductive therapy. Ropeginterferon alfa-2b treatment was not associated with ≥grade 3 anaemia in two recent clinical studies of 78 patients with PV. Only four cases of grade 2 anaemias occurred, the anaemia resolved. The mean haemoglobin levels were above 120.0 g/L. Therefore, ropeginterferon alfa-2b treatment does not lead to clinically significant anaemia and appears to manage PV without affecting normal erythropoiesis. “Both trials were registered at clinicaltrials.gov (A19-201: NCT04182100; A20-202: NCT05485948)”.